EUVIMEDObjevte EUVIMED
Crossref

Outcomes of Immunotherapy in Sinonasal Mucosal Melanoma Patients With Recurrent and Metastatic Disease

Ehiremen M Iyoha, Sarah M Jenkins, Ruifeng Guo, Garret Choby

Otolaryngology–Head and Neck Surgery · 2024-10 · 171 (4) · 1245-1249

DOI: 10.1002/ohn.850 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, 2024-10. Written by Ehiremen M Iyoha and 3 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Melanoma, Neoplasm Recurrence, Local, Immunotherapy, Nasal Mucosa. Cited 4 times so far (Crossref); 18 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Sinonasal mucosal melanoma (SNMM) is a rare malignancy with poor prognosis and high recurrence rate. In those with recurrence, survival is dismal. Immunotherapy is an emerging area of investigation; however, there is a scarcity of data on immunotherapy outcomes in SNMM patients with recurrence. We report outcomes of immunotherapy in recurrent SNMM patients with distant versus nondistant recurrence. Fifty‐four patients with recurrent SNMM were identified, and 31 (57.4%) had distant recurrence. One‐year overall survival (OS) following recurrence was 47.5% (95% confidence interval [CI]: 34.0%‐60.9%), with a median survival of 2.8 years (95% CI: 2.0‐5.3). In those with distant recurrence, receipt of immunotherapy was associated with better OS compared to those without immunotherapy (hazard ratio [HR] = 0.29 [95% CI: 0.12‐0.68], P = .004). While patients with nondistant recurrence (n = 23), who received immunotherapy (n = 6) had worse OS compared to those who did not receive immunotherapy (HR = 4.76 [95% CI: 1.36, 15.89], P = .02). Level of Evidence Level IV.

Subjects

MeSH terms (MEDLINE)

MelanomaNeoplasm Recurrence, LocalImmunotherapyNasal MucosaParanasal Sinus NeoplasmsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesTreatment OutcomeAdultSurvival RateAged, 80 and over

Author keywords

immunotherapyrecurrencesinonasal mucosal melanoma

Authors and institutions

  • Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Laboratory Medicine and Pathology, Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Cite

APA

Iyoha, E. M., Jenkins, S. M., Guo, R., & Choby, G. (2024). Outcomes of Immunotherapy in Sinonasal Mucosal Melanoma Patients With Recurrent and Metastatic Disease. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.850

Vancouver

Iyoha EM, Jenkins SM, Guo R, Choby G. Outcomes of Immunotherapy in Sinonasal Mucosal Melanoma Patients With Recurrent and Metastatic Disease. Otolaryngology–Head and Neck Surgery. 2024. doi:10.1002/ohn.850

BibTeX
@article{Iyoha2024,
  author = {Iyoha, Ehiremen M and Jenkins, Sarah M and Guo, Ruifeng and Choby, Garret},
  title = {Outcomes of Immunotherapy in Sinonasal Mucosal Melanoma Patients With Recurrent and Metastatic Disease},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2024},
  doi = {10.1002/ohn.850}
}
Start for free →